Hannah Lee practices high stakes patent litigation in federal courts throughout the country. She has served as trial counsel for her clients in ten multi-patent cases before federal district courts, the Patent Trial & Appeal Board and the International Trade Commission. Her practice focuses on representing clients in litigation and prosecution of innovative technologies in the areas of biotechnology, medical device, pharmaceuticals, and computer technologies.
Among her most notable recognitions, in 2020, Hannah represented Centripetal Networks Inc., a start-up computer security company, in the first federal trial conducted by videoconference on Zoom during the COVID-19 pandemic, and managed a team that obtained over $2 billion in damages after a six-week bench trial—the largest patent damages award in U.S. history. In 2019, her advocacy for a biotechnology client resulted in a judgment of noninfringement and dismissal of a patent lawsuit filed in the Southern District of New York involving protein expression technology and age-related macular degeneration treatment. She also represented a specialty pharmaceutical company in both district court litigation and before the Patent Trial and Appeal Board in inter partes review proceedings where she obtained a complete victory for her client adverse to the petitioner Purdue Pharma LP, resulting in a $62 million settlement in a patent litigation.
Hannah is a managing editor of Kramer Levin’s Bio Law Blog and is a member of the firm’s Women’s Committee, Diversity Committee and Attorneys of Color Affinity Group. She also enjoys helping clients on pro bono immigration matters. She is a 2007 graduate of Northwestern University School of Law and obtained a Bachelor of Science in Chemical Engineering from Stanford University in 2003.
Updated June 2021